Clinical Trials Logo

Major Depressive Episode clinical trials

View clinical trials related to Major Depressive Episode.

Filter by:

NCT ID: NCT04899609 Recruiting - Clinical trials for Major Depressive Episode

The Effects of Anger and Joy Expressions on Approach and Avoidance Behaviors in Healthy Volunteers

Start date: June 1, 2021
Phase:
Study type: Observational

Social interactions are part of our daily lives. Communicating with others is a recurring choice which is based on emotional cues, such as facial expression. Our action must be adapted to the emotional state of our interlocutor, otherwise the investigators will have poor quality interactions An emotional stimulus would cause a conditioned response (innate reaction). Thus, the presence of an angry person would automatically trigger flight behavior. More recently, however, it has been envisioned that this same avoidance behavior could be the result of a goal-directed behvior. In this case, the avoidance behavior would be the result of an evaluation of the consequences of the selected action. These goal-directed behaviors are guided by a mental representation of consequences The project aims to study behavioral choices (approach and avoidance) in response to negative and positive social cues (anger and joy) in 40 healthy volunteers using a computerized neuropsychological task, and to determine wheter these choices are the result of goal-directed behavior. The study also aims to assess the modulation of behavioral adaptation by the level of impulsivity, lonilness, empathy, and by the capcity to understand others' intenstions.

NCT ID: NCT04832750 Recruiting - Clinical trials for Major Depressive Disorder

Depression-Reduction by Accelerated Personalized NeuroModulation and Its Effects on Sleep

DREAMS
Start date: May 3, 2021
Phase:
Study type: Observational [Patient Registry]

Advances in repetitive transcranial magnetic stimulation (rTMS) protocols with intermittent theta-burst stimulation (iTBS) have significantly decreased the duration for one single session and thereby enabled accelerated treatment plans with multiple sessions per day, potentially reducing the total treatment duration. This randomized, placebo-controlled study investigates the effects of accelerated iTBS treatment with connectivity-informed neuronavigation on symptom severity, sleep, interoception, and cognitive control in patients with major depressive disorder and with or without comorbid borderline personality disorder using magnetic resonance imaging (MRI).

NCT ID: NCT04740463 Recruiting - Clinical trials for Major Depressive Episode

Assessement of Capacity to Consent

Start date: January 1, 2021
Phase:
Study type: Observational

Any patient can request euthanasia in many of our neighbouring European countries as long as informed consent is given. Psychiatric evaluation is not always mandatory. Faced with the increasing emergence of euthanasia requests in different countries from patients under psychiatric care in France for severe depressive episodes, question arises of a possible alteration in the capacity to give consent in the context of a severe depressive episode. This is a Social and Human Sciences study which does not aim to modify the usual management of patients.

NCT ID: NCT04480918 Recruiting - Clinical trials for Major Depressive Disorder

University of Iowa Interventional Psychiatry Service Patient Registry

Start date: November 2, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), racemic ketamine infusion and intranasal esketamine insufflation. The investigators will obtain various indicators, or biomarkers, of a depressed individuals' state before, during, and/or after these treatments. Such biomarkers include neurobehavioral testing, neuroimaging, electroencephalography, cognitive testing, vocal recordings, epi/genetic testing, and autonomic nervous system measures (i.e. "fight-or-flight" response). The results obtained from this study may provide novel antidepressant treatment response biomarkers, with the future goal of targeting a given treatment to an individual patient ("personalized medicine").

NCT ID: NCT04142996 Recruiting - Clinical trials for Major Depressive Episode

Comparing Uni- and Bi-lateral TBS in Major Depression

Start date: December 12, 2019
Phase: N/A
Study type: Interventional

Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS) is a very promising new treatment for major depression that allows a 15-fold reduction in duration of daily sessions. However, no large scale naturalistic study has assessed the superiority of bilateral TBS in comparison with unilateral left TBS. In fact, no TBS study thus far has included both unipolar and bipolar depression, or other psychiatric comorbidities such as anxiety. Maintenance has yet to be studied with TBS, along with an effective maintenance protocol to prevent relapse. Our study aims to explore and address these gaps.

NCT ID: NCT04130958 Recruiting - Suicide Clinical Trials

Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).

NCT ID: NCT03646058 Recruiting - Suicidal Ideation Clinical Trials

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

BUPRIS
Start date: October 10, 2021
Phase: Phase 3
Study type: Interventional

This study aims at investigating if adjunctive buprenorphine at low dose to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode, and at determining the most effective dose.

NCT ID: NCT03336918 Recruiting - Depression Clinical Trials

Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder

Start date: December 7, 2017
Phase:
Study type: Observational

Lithium is highly effective in the treatment of bipolar disorder. This study aims to investigate, for the first time, the impact of lithium monotherapy on the structural and functional connectivity of the brain using MRI imaging.

NCT ID: NCT02992496 Recruiting - Clinical trials for Major Depressive Episode

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment

Start date: April 24, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this double-blind, controlled, randomized study is to investigate the antidepressant efficacy of oral ketamine treatment in patients suffering from a major depressive episode.

NCT ID: NCT02824081 Recruiting - Clinical trials for Major Depressive Episode

Neuroinflammation, Serotonin, Impulsivity and Suicide

NISIS
Start date: November 2015
Phase: N/A
Study type: Interventional

Suicide is a major health problem that causes annually a million death worlwide. In the stress-vulnerability model, suicidal behavior (SB) results from the interaction between an individual's predisposition (personality, family history of SB…) and stressful conditions (early life adversity). Studies show that suicide ideations could favour inflammation and that depression is associated with an elevated inflammation. Recent evidences also suggest that inflammatory mediators play a critical role in SB. The aim of the study is to evaluate the inflammatory markers rate on depressed patients with or without personal history of SB. In the second part of the study, the relations between the rates of inflammatory markers and characteristics of SB, impulsivity, psychological pain, childhood abuse and gene expression of 5HT2B receptor will be investigated.